| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |